4 March 2025 - Skyrizi is the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease.

AbbVie announced today that Skyrizi (risankizumab) is now available in Canada for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to conventional therapy, a biologic treatment, or a Janus kinase inhibitor following Health Canada approval of this indication in October 2024.

Read AbbVie press release